Dear BNS member,
You will find on our COVID19 page the DHCP letter that AstraZeneca is sending to healthcare professionals in Belgium as a result of the evaluation by the PRAC (EMA). Upon request from the FAGG/AFMPS, this letter will be sent to all GPs, vaccination centres, internists, haematologists and emergency departments in Belgium. It is important to note that the content has been determined by the EMA and approved by the Belgian FAMHP.
The vaccine SmPC will be amended accordingly to mention this side effect.
We wanted to inform you as well, as this might also concern your daily practice, especially in view of the reports of cerebral venous thrombosis.
More information can be found on the EMA website: https://www.ema.europa.eu/en/news/astrazenecas-covid-19-vaccine-ema-finds-possible-link-very-rare-cases-unusual-blood-clots-low-blood
Please also see the recommendations for the management of coagulopathies from the BSTH, available on their website: https://www.bsth.be/professionals